Results 41 to 50 of about 1,438 (185)

Myositis mimics

open access: yesIndian Journal of Rheumatology, 2021
Proximal muscle weakness in children, as well as adults, can be the presenting feature of a wide range of diseases including but not limited to the idiopathic inflammatory myopathies, muscle dystrophies, metabolic, endocrine, and drug-induced myopathies.
Sujata Ganguly   +3 more
doaj   +1 more source

В6.А-DYSFPRMD/GENEJ MICE AS A GENETIC MODEL OF DYSFERLINOPATHY

open access: yesФармация и фармакология (Пятигорск), 2022
The aim of the work was behavioral and pathomorphological phenotyping of the mice knockout for the DYSF gene, which plays an important role in the development and progression of dysferlinopathy.Materials and methods.
M. V. Korokin   +15 more
doaj   +1 more source

A rare case of dysferlinopathy with paternal isodisomy for chromosome 2 determined by exome sequencing

open access: yesMolecular Genetics & Genomic Medicine, 2023
Background Dysferlinopathies are autosomal recessive muscular dystrophies resulting from defects in DYSF (MIM: 603009), which is located on chromosome 2p13 and encodes the dysferlin protein. Methods We performed exome sequencing and subsequent trio‐based
Huan Li, Liang Wang, Cheng Zhang
doaj   +1 more source

Clinical Heterogeneity in Dysferlinopathy.

open access: yesInternal Medicine, 2002
To clarify the clinical heterogeneity and genotype-phenotype correlation in dysferlinopathy.We evaluated clinical parameters of 74 dysferlinopathy patients with known dysferlin gene mutations who were previously reported in the literature.The age at onset varied from 12 to 59 years (mean 21.7 years).
UEYAMA, Hidetsugu   +5 more
openaire   +3 more sources

Exon Skipping in a Dysf-Missense Mutant Mouse Model

open access: yesMolecular Therapy: Nucleic Acids, 2018
Limb girdle muscular dystrophy 2B (LGMD2B) is without treatment and caused by mutations in the dysferlin gene (DYSF). One-third is missense mutations leading to dysferlin aggregation and amyloid formation, in addition to defects in sarcolemmal repair and
Jakub Malcher   +10 more
doaj   +1 more source

Functions of Vertebrate Ferlins

open access: yesCells, 2020
Ferlins are multiple-C2-domain proteins involved in Ca2+-triggered membrane dynamics within the secretory, endocytic and lysosomal pathways. In bony vertebrates there are six ferlin genes encoding, in humans, dysferlin, otoferlin, myoferlin, Fer1L5 and 6
Anna V. Bulankina, Sven Thoms
doaj   +1 more source

A female case report of LGMD2B with compound heterozygous mutations of the DYSF gene and asymptomatic mutation of the X-linked DMD gene

open access: yesFrontiers in Neurology, 2023
We report the case of a 31-year-old Chinese woman with a chief complaint of weakness in the lower limbs, which was diagnosed as limb-girdle muscular dystrophy 2B (LGMD2B) with compound heterozygous mutations of the DYSF gene.
Xiaojie Cao   +6 more
doaj   +1 more source

Thrombospondin-1 and disease progression in dysferlinopathy [PDF]

open access: yesHuman Molecular Genetics, 2017
The purpose of this study was to determine whether thrombospondin (TSP)-1 promotes macrophage activity and disease progression in dysferlinopathy. First, we found that levels of TSP-1 are elevated in blood of non-ambulant dysferlinopathy patients compared with ambulant patients and healthy controls, supporting the idea that TSP-1 levels are correlated ...
Norifumi Urao   +5 more
openaire   +2 more sources

Deep phenotyping of an international series of patients with late‐onset dysferlinopathy

open access: yes, 2021
International audienceBackground: To describe the clinical, pathological, and molecular characteristics of late-onset (LO) dysferlinopathy patients.Methods: Retrospective series of patients with LO dysferlinopathy, defined by an age at onset of symptoms ≥
Bedat-Millet, Anne-Laure   +53 more
core   +1 more source

Effects of Prednisone on a Patient with Dysferlinopathy Assessed by Maximal Voluntary Isometric Contraction: Alternate-Day Low-Dose Administration for a 17-Year Period

open access: yesCase Reports in Neurology, 2019
Glucocorticoids are candidates for the pharmacological treatment of dysferlinopathy. Deflazacort, however, showed a worse effect on muscle strength than placebo.
Keiichi Takahashi
doaj   +1 more source

Home - About - Disclaimer - Privacy